INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on November 5, 2020. The report details corporate actions regarding the Company's capital structure, specifically a reverse stock split and a reduction in authorized shares, effective November 9, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on corporate governance and capital structure adjustments rather than financial performance.
Material Changes
- Authorized Shares: Decreased from 200,000,000 to 125,000,000 shares.
- Reverse Stock Split: A 5-for-8 reverse stock split was effectuated.
- Outstanding Shares: Reduced from 7,926,255 shares prior to the split to 4,953,910 shares post-split (subject to rounding of fractional shares).
- Trading Symbol: Remains "INVO" on OTCMKTS, but a "D" suffix was applied for 20 business days to indicate the split.
- CUSIP Number: Updated to 44984F302 following the split.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The primary operational note is the administrative requirement for the reverse split to take effect at the open of business on November 9, 2020, as confirmed by FINRA/OTC Corporate Actions.
Investor Verification Checklist
- Verify the new share count of 4,953,910 in brokerage accounts post-November 9, 2020.
- Confirm the updated CUSIP number (44984F302) for trading purposes.
- Monitor the ticker symbol for the temporary "D" suffix indicating the corporate action.
- Review the Certificate of Change (Exhibit 3.1) for specific terms regarding fractional share settlement.